Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 July 2023 | Story Leonie Bolleurs | Photo Supplied
iKudu Coil Chevon Slammbee
Chevon Slambee says the COIL approach connects students and educators from different cultural backgrounds through online platforms, allowing participants to engage in cross-cultural learning and collaboration.

Internationalisation of the curriculum has been mandatory for institutions of higher education since 2020, according to the National Policy Framework for the Internationalisation of Higher Education in South Africa.

The iKudu project, an Erasmus+Capacity-Building in Higher Education (CBHE) co-funded project, which aims, among others, for universities to include internationalisation and decolonisation dimensions to transform their curricula, recently published the document: Considerations for enabling guidelines, strategies, and policies for internationalised curriculum renewal for universities with a focus on the diverse South African contexts. 

The University of the Free State (UFS) Office for International Affairs (OIA) played a key role in the publication of this document.

In his editorial of the document, Dr Cornelius Hagenmeier, Director of the OIA, states that in the spirit of the iKudu values – which include Ubuntu, trust, and equality – the project stakeholders have developed a document that will serve as a repository of ideas from which all consortium member universities can intelligently borrow when developing their institutional guidelines, strategies, and policies for curriculum renewal, Collaborative Online International Learning (COIL), or other forms of virtual exchange.

He says they are publishing this document to make the ideas available to the broader higher education community, in the hope that they will contribute to further debate on internationalised curriculum renewal processes.

The iKudu project is one of the few major EU-funded capacity-building projects coordinated by a South African university.

UFS coordinates iKudu

According to Chevon Slambee, iKudu Project Manager in the UFS OIA, the consideration document serves as a guiding document for all universities, but specifically focuses on South African universities, taking into account the unique and diverse contexts of South Africa’s higher education landscape and how these contexts influence the curriculum renewal processes.

Slambee explains that the COIL approach connects students and educators from different cultural backgrounds through online platforms, allowing participants to engage in cross-cultural learning and collaboration within the existing curriculum. 

Through joint projects, shared courses, and virtual exchanges, it aims to foster intercultural competence, global awareness, and mutual understanding among students. Moreover, the initiative creates inclusive opportunities for all students who take part in COIL, as the inequalities due to financial resources are factored out. “It expands the classroom beyond classroom borders, and grants students the opportunity to engage in a digital international world,” says Slambee. 

The five participating South African universities – the UFS, Durban University of Technology, University of Limpopo, University of Venda, and the Central University of Technology – together with the five European universities – the University of Siena (Italy), Coventry University (England), The Hague University of Applied Sciences (The Netherlands), Amsterdam University of Applied Sciences (The Netherlands), and the University of Antwerp (Belgium) – have implemented 51 of their target of 55 COIL programmes, with almost 10 months remaining in the project. “For us, this is a milestone in the iKudu journey,” says Slambee. 

Sharing COIL experiences

One of the UFS lecturers who completed a COIL project is Prof Mariette Reyneke, Associate Professor in the UFS Department of Public Law.

Prof Reyneke recently completed her second COIL experience, this time with Prof Alessandra Viviani from the University of Siena. She says one of the best aspects of this initiative is giving our students the opportunity to broaden their horizons by exposing them to peers from a different country and culture. “Moreover, one also gets to expose students from developed countries to the realities and challenges of a developing country,” she adds.

“Through this initiative, we also get the chance to teach South African students that they have valuable contributions to offer the world. In some instances, our legal solutions to problems are fascinating and enriching for international students. Our theory and implementation of human rights are also sometimes more liberal than what students from Europe experience in their own countries,” says Prof Reyneke, who believes that COIL fosters an innovative and enriching experience for students, while also enhancing academic networks.

“It was very satisfying for me to realise that the students not only enjoyed the experience, but also found it beneficial for their personal growth,” she remarks.

Moving forward, Slambee says the OIA is working closely with the Centre for Teaching and Learning and is in the process of establishing a COIL/virtual engagement hub for the university. Furthermore, the Curriculum Internationalisation Project (CIP) has been approved and is being piloted in specific departments and faculties. For more information about the CIP, contact Prof Lynette Jacobs, Slambee, or Nooreen Adam from the OIA.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept